Akari Therapeutics (NASDAQ:AKTX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a report released on Saturday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Down 1.2 %

Shares of NASDAQ:AKTX opened at $0.97 on Friday. The company’s 50 day moving average is $1.63 and its 200 day moving average is $2.73. Akari Therapeutics has a twelve month low of $0.90 and a twelve month high of $4.40.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.